pcn poster

Posters

Long-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression: final results of the SUSTAIN-3 study

In a long-term study (up to 6.6 years) of intermittently-dosed esketamine with daily antidepressant, early improvement in depression was maintained and no new safety signal was identified...

Naim Zaki , MD;

10/26/2023

Long-Term Safety of Esketamine Nasal Spray Dosed in Accordance With US Prescribing Information in Adults With Treatment-Resistant Depression: A Subgroup Analysis of the SUSTAIN-3 Study Up to 6.5 Years

This subgroup analysis of SUSTAIN-3 (NCT02782104), an open-label extension study of esketamine nasal spray (ESK), assessed the long-term safety of flexibly dosed ESK in combination with a...

Toya Bowles , PharmD, MS, BCPP;

10/26/2023

Long-Term Safety of Once-Nightly Sodium Oxybate for Narcolepsy: RESTORE Study Interim Analysis of Data

The ongoing RESTORE trial is an open-label/switch study evaluating the safety and tolerability of a once-at-bedtime oxybate (ON-SXB). Interim data from RESTORE suggest that the safety pro...

Thomas Stern , MD;

10/26/2023

Key Characteristics of the Long-Acting Injectable Atypical Antipsychotic Aripiprazole Lauroxil for the Treatment of Adults with Schizophrenia

Aripiprazole lauroxil and its 1-day initiation formulation were specifically developed using an innovative prodrug technology to provide long-acting injectable formulations of aripiprazol...

Andrew J. Cutler , MD;

10/26/2023

Left Frontal lobe Meningioma masquerading as Schizophrenia

Frontal lobe tumors are known to alter whole personality, not just memory and retention. They are not easily suspected and missed in patients diagnosed with a psychiatric disorder. We pre...

Rohit Madan , MD;

10/26/2023

Investigating Care Models to Support Older Adults with Depression and Health Comorbidities

An online survey of older adults living with depression and health comorbidities and their care-partners (n = 571; 73.4 % patients and 14.0% peers) was undertaken to identify treatment pr...

Rebecca A. Dickinson , BSc, BA;

10/26/2023

Is It Their Eyes? - Could Your Patients' Psych Symptoms be Due to Binocular Vision Disorder?

This poster shares basic information on BVD - signs, symptoms, causes, screening tools, to educate those in the position of psychiatric evaluation on a potential non-psychiatric etiology ...

Jenna Shock , MSN-ED, APRN, PMHNP-BC;

10/26/2023

Key Characteristics of the Long-Acting Injectable Atypical Antipsychotic Aripiprazole Lauroxil for the Treatment of Adults with Schizophrenia

Aripiprazole lauroxil and its 1-day initiation formulation were specifically developed using an innovative prodrug technology to provide long-acting injectable formulations of aripiprazol...

James A. McGrory , PhD;

10/26/2023

Improvements in Depressive Symptoms in Patients With Major Depressive Disorder: Analysis of Zuranolone Efficacy From 4 Randomized, Placebo-Controlled Trials

An analysis of 4 randomized, placebo-controlled trials evaluating a 14-day treatment course of zuranolone 30- or 50-mg in adults with MDD showed nominally significant improvements (p ...

Anita H. Clayton , MD;

10/26/2023

Incidence and Characteristics of Akathisia With Adjunctive Cariprazine Treatment in Patients With Major Depressive Disorder

Incidence of akathisia was higher for cariprazine than placebo, with lower incidence observed for patients treated with cariprazine 1.5mg/d+ADT versus 3mg/d+ADT, suggesting dose related e...

Majid Kerolous , PharmD, MPH;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products